Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Halcion

(Triazolam)

ApprovedSmall molecule

Halcion is one of 37 small molecule programs targeting Age. It is currently in Approved.

2

Indications

9

Total Trials

1

Active Trials

36

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

AgeCompleted

AgePreclinical

Completed

Competition

Competitive Landscape

49 competitors in Age

#DrugCompanyPhaseTrials

Actigall

Rapamune

PPrism Pharmaceuticals

Halcion

Decadron

AAspen Global Incorporated

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Rezurock

KKadmon, a Sanofi Company

Venclexta

Acotiamide

APG-2575

Ascentage Pharma Group Inc.

Evorpacept

AALX Oncology Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

MPA

NCT03954483

Clinical

Trials by Indication[1]

Esketamine1 trial

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01780259·58 enrolled

Driving1 trial

Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT01888497·59 enrolled

Oral1 trial

A Study to Determine Whether an Oral Drops Formulation of Triazolam is Bioequivalent to a Tablet Formulation in Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT01421043·34 enrolled

MPA1 trial

Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal

Recruiting·UUniversity of Manitoba·N/A·NCT03954483·42 enrolled

Treatment1 trial

Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient

Completed·UUniversity of Pittsburgh·N/A·NCT03360123·4 enrolled

4 more indications

Absorption1 trial

Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT01017926

Age1 trial

Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents

Completed·AAkili Interactive Labs, Inc.·N/A·NCT02822937·18 enrolled

Sedation1 trial

Oral Versus Intravenous Sedation for Ocular Procedures

Completed·—·Phase 4·NCT03246724·327 enrolled

Unspecified1 trial

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 26, 1985

HALCION

NDA NDA017892

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Triazolam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triazolam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triazolam. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA017892). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

Related News